Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites


Wafik S El-Deiry, Namrata Vijayvergia, Joanne Xiu, Angelique Scicchitano, Bora Lim, Nelson S Yee, Harold A Harvey, Zoran Gatalica, Sandeep Reddy


Metastatic colorectal cancer (mCRC) carries a poor prognosis with an overall 5-year survival of 13.1%. Therapies guided by tumor profiling have suggested benefit in advanced cancer. We used a multiplatform molecular profiling (MP) approach to identify key molecular changes that may provide therapeutic options not typically considered in mCRC.

External Link